MedTrace Logo

A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes

NCT02384096 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-11-20

Study results available
· View outcomes & findings →

Summary

The study is a prospective, on-label, multi-center, blinded, randomized controlled trial with a cross-over design to evaluate the effect of Precision Spectra™ SCS System's programming features and lead options.

Conditions

Interventions

DEVICE

Conventional single source programming

Precision Spectra SCS System using conventional single source programming.

DEVICE

Precision Spectra SCS System advanced programming

Precision Spectra SCS System using advanced programming

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Kristen Lechleiter, M.S. · Boston Scientific Neuromodulation Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02384096 on ClinicalTrials.gov